NASDAQ:SDGR Schrödinger (SDGR) Stock Price, News & Analysis → A Silent Invasion of America (From The Freeport Society) (Ad) Free SDGR Stock Alerts $21.06 -0.16 (-0.75%) (As of 11:15 AM ET) Add Compare Share Share Today's Range$20.73▼$21.0750-Day Range$21.00▼$28.5052-Week Range$20.56▼$59.24Volume108,715 shsAverage Volume813,416 shsMarket Capitalization$1.53 billionP/E RatioN/ADividend YieldN/APrice Target$42.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Schrödinger alerts: Email Address Schrödinger MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside103.2% Upside$42.80 Price TargetShort InterestBearish10.66% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.86Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.70) to ($1.66) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.18 out of 5 starsMedical Sector773rd out of 917 stocksPharmaceutical Preparations Industry362nd out of 431 stocks 3.3 Analyst's Opinion Consensus RatingSchrödinger has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageSchrödinger has only been the subject of 2 research reports in the past 90 days.Read more about Schrödinger's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.66% of the outstanding shares of Schrödinger have been sold short.Short Interest Ratio / Days to CoverSchrödinger has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.Change versus previous monthShort interest in Schrödinger has recently decreased by 1.77%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldSchrödinger does not currently pay a dividend.Dividend GrowthSchrödinger does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SDGR. Previous Next 2.1 News and Social Media Coverage News SentimentSchrödinger has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Schrödinger this week, compared to 3 articles on an average week.Search InterestOnly 5 people have searched for SDGR on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Schrödinger to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Schrödinger insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.60% of the stock of Schrödinger is held by insiders.Percentage Held by Institutions79.05% of the stock of Schrödinger is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Schrödinger's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Schrödinger are expected to grow in the coming year, from ($2.70) to ($1.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Schrödinger is -11.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Schrödinger is -11.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSchrödinger has a P/B Ratio of 2.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Schrödinger's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe Single Biggest Breakthrough of the Decade Billionaires, Jeff Bezos, Bill Gates, Warren Buffett, and Sir Richard Branson are rallying behind this technology as well. In my new investigation, I detail why this technology is the single biggest breakthrough of the decade.Click here to watch it now. About Schrödinger Stock (NASDAQ:SDGR)Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.Read More SDGR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SDGR Stock News HeadlinesJune 14 at 8:30 AM | businesswire.comSchrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)June 12 at 8:42 AM | americanbankingnews.comSchrödinger (NASDAQ:SDGR) Sets New 12-Month Low at $20.75June 4, 2024 | seekingalpha.comSchrodinger: Buy The Drug-Discovery Platform And Get The Pipeline Nearly For FreeJune 1, 2024 | 247wallst.com1 Growth Stock That Could Dominate AI's Next BreakthroughMay 22, 2024 | msn.com3 Small-Cap Stocks to Invest in AI Drug DevelopmentMay 22, 2024 | businesswire.comSchrödinger to Present at Jefferies Global Healthcare ConferenceMay 17, 2024 | businesswire.comSchrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 16, 2024 | morningstar.comSchrodinger Inc Ordinary SharesMay 16, 2024 | investorplace.com7 Pharma Stocks Harnessing AI Brainpower for Big BreakthroughsMay 7, 2024 | seekingalpha.comSchrödinger: More Pharmaceutical Than SoftwareMay 3, 2024 | markets.businessinsider.comMaintaining Neutral: Assessing Schrodinger’s Mixed Q1 Performance and Future OutlookMay 3, 2024 | finance.yahoo.comSchrödinger, Inc. (NASDAQ:SDGR) Q1 2024 Earnings Call TranscriptMay 2, 2024 | markets.businessinsider.comMaintained Buy Rating on Schrodinger: Navigating Short-Term Hurdles with Long-Term Catalysts in SightMay 2, 2024 | markets.businessinsider.comMaintaining Buy Rating on Schrodinger: Solid Fundamentals and Promising Pipeline Despite Quarterly MissMay 1, 2024 | seekingalpha.comSchrödinger, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 1, 2024 | msn.comSchrödinger misses top-line and bottom-line estimates; initiates Q2 and reaffirms FY24 outlookMay 1, 2024 | finance.yahoo.comSchrodinger Inc (SDGR) Misses Revenue Expectations in Q1 2024May 1, 2024 | businesswire.comSchrödinger Reports First Quarter 2024 Financial ResultsApril 30, 2024 | msn.comSchrödinger Q1 2024 Earnings PreviewApril 18, 2024 | businesswire.comSchrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 11, 2024 | finance.yahoo.comInstitutional investors must be pleased after a 11% gain last week that adds to Schrödinger, Inc.'s (NASDAQ:SDGR) one-year returnsApril 10, 2024 | businesswire.comSchrödinger to Announce First Quarter 2024 Financial Results on May 1April 2, 2024 | investorplace.com5 Healthcare Stocks to Buy for 2024April 1, 2024 | msn.com9 Noteworthy Stocks in Bill Gates’ PortfolioMarch 27, 2024 | investorplace.comInvest Like Bill Gates With These 3 AI Stocks to BuySee More Headlines Receive SDGR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Schrödinger and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today6/13/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SDGR CUSIPN/A CIK1490978 Webwww.schrodinger.com Phone212-295-5800FaxN/AEmployees867Year FoundedN/APrice Target and Rating Average Stock Price Target$42.80 High Stock Price Target$67.00 Low Stock Price Target$26.00 Potential Upside/Downside+101.7%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$40.72 million Net Margins-75.94% Pretax Margin-88.52% Return on Equity-29.25% Return on Assets-20.60% Debt Debt-to-Equity RatioN/A Current Ratio4.64 Quick Ratio4.64 Sales & Book Value Annual Sales$188.48 million Price / Sales8.18 Cash Flow$0.64 per share Price / Cash Flow33.29 Book Value$7.60 per share Price / Book2.79Miscellaneous Outstanding Shares72,679,000Free Float66,429,000Market Cap$1.54 billion OptionableOptionable Beta1.53 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Ramy Farid Ph.D. (Age 59)CEO, President & Director Comp: $1.06MDr. Richard A. Friesner Ph.D. (Age 71)Co-Founder, Scientific Advisory Chairman and Director Comp: $465kDr. Geoffrey Craig Porges MBBSExecutive VP & CFODr. Robert Lorne Abel Ph.D. (Age 42)Executive VP, Chief Scientific Officer of Platform and Head of Modeling R&D Comp: $569.45kDr. Karen Akinsanya Ph.D. (Age 56)President of Research & Development Therapeutics Comp: $797.74kDr. Margaret Han Dugan M.D. (Age 67)Chief Medical Officer Comp: $707.46kProf. William Goddard IIICo-Founder & Scientific AdvisorMr. Kenneth Patrick Lorton (Age 40)Executive VP, CTO & COO of Software Comp: $510.09kMr. Shane Brauner (Age 46)Executive VP & Chief Information Officer Ms. Jaren Irene MaddenSenior Vice President of Investor Relations & Corporate CommunicationsMore ExecutivesKey CompetitorsSage TherapeuticsNASDAQ:SAGEEmergent BioSolutionsNYSE:EBSAllakosNASDAQ:ALLKTurning Point TherapeuticsNASDAQ:TPTXForty SevenNASDAQ:FTSVView All CompetitorsInsiders & InstitutionsDekaBank Deutsche GirozentraleSold 228,600 shares on 6/4/2024Ownership: 0.028%Virtu Financial LLCBought 9,757 shares on 5/20/2024Ownership: 0.013%Comerica BankSold 2,753 shares on 5/17/2024Ownership: 0.032%Walleye Trading LLCBought 3,500 shares on 5/17/2024Ownership: 0.000%California State Teachers Retirement SystemSold 2,800 shares on 5/16/2024Ownership: 0.085%View All Insider TransactionsView All Institutional Transactions SDGR Stock Analysis - Frequently Asked Questions Should I buy or sell Schrödinger stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Schrödinger in the last twelve months. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SDGR shares. View SDGR analyst ratings or view top-rated stocks. What is Schrödinger's stock price target for 2024? 9 Wall Street analysts have issued 12-month price objectives for Schrödinger's stock. Their SDGR share price targets range from $26.00 to $67.00. On average, they anticipate the company's stock price to reach $42.80 in the next twelve months. This suggests a possible upside of 103.2% from the stock's current price. View analysts price targets for SDGR or view top-rated stocks among Wall Street analysts. How have SDGR shares performed in 2024? Schrödinger's stock was trading at $35.80 at the beginning of 2024. Since then, SDGR stock has decreased by 41.2% and is now trading at $21.06. View the best growth stocks for 2024 here. When is Schrödinger's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our SDGR earnings forecast. How were Schrödinger's earnings last quarter? Schrödinger, Inc. (NASDAQ:SDGR) issued its earnings results on Wednesday, May, 1st. The company reported ($0.76) earnings per share for the quarter, meeting the consensus estimate of ($0.76). The firm earned $36.60 million during the quarter, compared to the consensus estimate of $41.23 million. Schrödinger had a negative trailing twelve-month return on equity of 29.25% and a negative net margin of 75.94%. What ETFs hold Schrödinger's stock? ETFs with the largest weight of Schrödinger (NASDAQ:SDGR) stock in their portfolio include Northern Lights Fund Trust IV - Long Cramer Tracker ETF (LJIM), Subversive Mental Health ETF (SANE), ARK Genomic Revolution ETF (ARKG), TrueShares Technology, AI & Deep Learning ETF (LRNZ), Tema Oncology ETF (CANC), Range Cancer Therapeutics ETF (CNCR), Loncar China Biopharma ETF (CHNA) and Invesco S&P SmallCap Health Care ETF (PSCH). What guidance has Schrödinger issued on next quarter's earnings? Schrödinger issued an update on its FY 2024 earnings guidance on Wednesday, May, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $198.7 million-$214.8 million, compared to the consensus revenue estimate of $206.7 million. What is Ramy Farid's approval rating as Schrödinger's CEO? 8 employees have rated Schrödinger Chief Executive Officer Ramy Farid on Glassdoor.com. Ramy Farid has an approval rating of 95% among the company's employees. This puts Ramy Farid in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Schrödinger own? Based on aggregate information from My MarketBeat watchlists, some companies that other Schrödinger investors own include NVIDIA (NVDA), Marvell Technology (MRVL), Tesla (TSLA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Block (SQ), Cisco Systems (CSCO), Teladoc Health (TDOC), Alteryx (AYX) and QUALCOMM (QCOM). When did Schrödinger IPO? Schrödinger (SDGR) raised $150 million in an IPO on Thursday, February 6th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Securities, Jefferies and BMO Capital Markets served as the underwriters for the IPO. Who are Schrödinger's major shareholders? Schrödinger's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.42%), Baillie Gifford & Co. (3.61%), Sumitomo Mitsui Trust Holdings Inc. (3.03%), Nikko Asset Management Americas Inc. (1.78%), Lazard Asset Management LLC (1.67%) and Tocqueville Asset Management L.P. (1.24%). Insiders that own company stock include David E Shaw, Jenny Herman, Joel Lebowitz, Karen Akinsanya, Kenneth Patrick Lorton, Nancy Thornberry, Ramy Farid, Robert Lorne Abel and Yvonne Tran. View institutional ownership trends. How do I buy shares of Schrödinger? Shares of SDGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SDGR) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | SponsoredExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Schrödinger, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Schrödinger With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.